Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir Tolmachev

Showing results (1-10 of 304) with videos related to

Pageof 31
Sort By:
Current Radiopharmaceuticals|December 24, 2011
Radiobromine-labelled tracers for positron emission tomography: possibilities and pitfallsVladimir Tolmachev
Cancers|March 15, 2020
Affibody Molecules as Targeting Vectors for PET ImagingVladimir Tolmachev, Anna Orlova
Cancers|January 21, 2022
Radionuclides in Diagnostics and Therapy of Malignant Tumors: New DevelopmentVladimir Tolmachev, Anzhelika Vorobyeva
Current Pharmaceutical Biotechnology|May 26, 2010
Radionuclide molecular imaging using Affibody moleculesSara Ahlgren, Vladimir Tolmachev
Biopolymers|March 27, 2003
Targeting peptides and positron emission tomographyHans Lundqvist, Vladimir Tolmachev
Methods in Molecular Biology (Clifton, N.J.)|June 28, 2012
Engineering of affibody molecules for therapy and diagnosticsJoachim Feldwisch, Vladimir Tolmachev
Biochimica Et Biophysica Acta|February 16, 2010
Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methodsVladimir Tolmachev, Sharon Stone-Elander
Current Opinion in Drug Discovery & Development|April 18, 2007
Affibody molecules: new protein domains for molecular imaging and targeted tumor therapyFredrik Y Nilsson, Vladimir Tolmachev
Seminars in Cancer Biology|January 19, 2021
The emerging role of radionuclide molecular imaging of HER2 expression in breast cancerVladimir Tolmachev, Anna Orlova, Jens Sörensen
Physics in Medicine and Biology|March 20, 2002
Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapyMark Lubberink, Hans Lundqvist, Vladimir Tolmachev
Pageof 31

Showing results (1-10 of 304) with videos related to

Sort By:
Pageof 31
Current Radiopharmaceuticals|December 24, 2011
Radiobromine-labelled tracers for positron emission tomography: possibilities and pitfallsVladimir Tolmachev
Cancers|March 15, 2020
Affibody Molecules as Targeting Vectors for PET ImagingVladimir Tolmachev, Anna Orlova
Cancers|January 21, 2022
Radionuclides in Diagnostics and Therapy of Malignant Tumors: New DevelopmentVladimir Tolmachev, Anzhelika Vorobyeva
Current Pharmaceutical Biotechnology|May 26, 2010
Radionuclide molecular imaging using Affibody moleculesSara Ahlgren, Vladimir Tolmachev
Biopolymers|March 27, 2003
Targeting peptides and positron emission tomographyHans Lundqvist, Vladimir Tolmachev
Methods in Molecular Biology (Clifton, N.J.)|June 28, 2012
Engineering of affibody molecules for therapy and diagnosticsJoachim Feldwisch, Vladimir Tolmachev
Biochimica Et Biophysica Acta|February 16, 2010
Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methodsVladimir Tolmachev, Sharon Stone-Elander
Current Opinion in Drug Discovery & Development|April 18, 2007
Affibody molecules: new protein domains for molecular imaging and targeted tumor therapyFredrik Y Nilsson, Vladimir Tolmachev
Seminars in Cancer Biology|January 19, 2021
The emerging role of radionuclide molecular imaging of HER2 expression in breast cancerVladimir Tolmachev, Anna Orlova, Jens Sörensen
Physics in Medicine and Biology|March 20, 2002
Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapyMark Lubberink, Hans Lundqvist, Vladimir Tolmachev
Pageof 31